Predictive Factors and Prognostic Relevance of Sunitinib-induced Subclinical and Overt Hypothyroidism in Korean Patients with Metastatic Renal Cell Carcinoma
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: Sunitinib, commonly used for metastatic renal cell carcinoma (mRCC), often induces hypothyroidism, affecting 27 to 85% of patients. There are clues suggesting an association between sunitinib-induced hypothyroidism and improved survival out comes. This study aims to identify the predictive factors of sunitinib-induced hypothyroidism and evaluate whether the occurrence of overt or subclinical hypothyroidism predicts tumor outcome in patients with mRCC. Methods: Patients administered to sunitinib for mRCC was included in this retrospective study. Log-rank test and Cox proportional hazards model were conducted to identify predictive factors of hypothyroidism and prognostic factors of progression-free survival (PFS) and overall survival (OS). Results: A total of 156 patients with mRCC treated with sunitinib were included. Predictive factors of sunitinib-induced hypothyroidism were female (odds ratio (OR), 2.77), sunitinib-induced hypertension (OR, 2.99) and dose reduction of sunitinib due to intolerance (OR, 3.57). Sunitinib-induced overt hypothyroidism was a significant prognostic factor in predicting PFS and OS (hazard ratio, 0.38 and 0.23, respectively). Thyroid hormone replacement did not have an influence on PFS and OS. Conclusions: Female patients, patients who experienced sunitinib-induced hypertension and sunitinib dose reduction are at higher risk of hypothyroidism and need close monitoring. Overt hypothyroidism is a strong prognostic factor of sunitinib treatment outcome in mRCC patients and thyroid hor mone replacement does not have a negative effect on tumor outcome.
Abstract
Background: Sunitinib, commonly used for metastatic renal cell carcinoma (mRCC), often induces hypothyroidism, affecting 27 to 85% of patients. There are clues suggesting an association between sunitinib-induced hypothyroidism and improved survival out comes. This study aims to identify the predictive factors of sunitinib-induced hypothyroidism and evaluate whether the occurrence of overt or subclinical hypothyroidism predicts tumor outcome in patients with mRCC. Methods: Patients administered to sunitinib for mRCC was included in this retrospective study. Log-rank test and Cox proportional hazards model were conducted to identify predictive factors of hypothyroidism and prognostic factors of progression-free survival (PFS) and overall survival (OS). Results: A total of 156 patients with mRCC treated with sunitinib were included. Predictive factors of sunitinib-induced hypothyroidism were female (odds ratio (OR), 2.77), sunitinib-induced hypertension (OR, 2.99) and dose reduction of sunitinib due to intolerance (OR, 3.57). Sunitinib-induced overt hypothyroidism was a significant prognostic factor in predicting PFS and OS (hazard ratio, 0.38 and 0.23, respectively). Thyroid hormone replacement did not have an influence on PFS and OS. Conclusions: Female patients, patients who experienced sunitinib-induced hypertension and sunitinib dose reduction are at higher risk of hypothyroidism and need close monitoring. Overt hypothyroidism is a strong prognostic factor of sunitinib treatment outcome in mRCC patients and thyroid hor mone replacement does not have a negative effect on tumor outcome.
참고문헌 (28)
- Wu J, "Acquired Hypothyroidism in Patients with Metastatic Renal Cell Carcinoma Treated with Tyrosine Kinase Inhibitors", Drug Des Devel Ther, 28(14), pp.3977~3982 (2020)
- Sabatier R, "Could thyroid dysfunction influence outcome in sunitinib-treated metastatic renal cell carcinoma?", Ann Oncol, 23(3), pp.714~721 (2012)
- Wolter P, "The clinical implications of sunitinib-induced hypothyroidism : a prospective evaluation", Br J Cancer, 99(3), pp.448~454 (2008)
- Ozao-Choy J, "The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies", Cancer Res, 69(6), pp.2514~2522 (2009)
- Kim DS, "Interactions between Polygenetic Variants and Lifestyle Factors in Hypothyroidism : A Hospital-Based Cohort Study", Nutrients, 15(17), pp.3850~ (2023)
- Inoue K, "Association of Subclinical Hypothyroidism and Cardiovascular Disease With Mortality", JAMA Netw Open, 3(2), pp.e1920745~ (2020)
- Thvilum M, "A review of the evidence for and against increased mortality in hypothyroidism", Nat Rev Endocrinol, 8(7), pp.417~424 (2012)
- Bozkurt O, "Is sunitinib-induced hypothyroidism a predictive clinical marker for better response in metastatic renal cell carcinoma patients?", J Chemother, 28(3), pp.230~234 (2016)
- Kust D, "Hypothyroidism as a predictive clinical marker of better treatment response to sunitinib therapy", Anticancer Res, 34(6), pp.3177~3184 (2014)
- Bolzacchini E, "On-target Toxicities Predictive of Survival in Metastatic Renal Cell Carcinoma(mRCC)Treated With Sunitinib : A Multicenter Retrospective Study", Clin Genitourin Cancer, 18(2), pp.e145~56 (2020)
- Shinohara N, "The incidence and mechanism of sunitinib-induced thyroid atrophy in patients with metastatic renal cell carcinoma", Br J Cancer, 104(2), pp.241~247 (2011)
- Surks MI, "American Thyroid Association guidelines for use of laboratory tests in thyroid disorders", JAMA, 263(11), pp.1529~1532 (1990)
- Heng DY, "Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents : results from a large, multicenter study", J Clin Oncol, 27(34), pp.5794~5799 (2009)
- Torino F, "Hypothyroidism related to tyrosine kinase inhibitors : an emerging toxic effect of targeted therapy", Nat Rev Clin Oncol, 6(4), pp.219~228 (2009)
- Clemons J, "Thyroid dysfunction in patients treated with sunitinib or sorafenib", Clin Genitourin Cancer, 10(4), pp.225~231 (2012)
- Ismael Pinto FA, "Association of hypothyroidism with improved outcomes in firstline treatment of renal cell carcinoma with sunitinib", J Clin Oncol, 30(Suppl 5), pp.466~ (2012)
- Baldazzi V, "The impact of sunitinib-induced hypothyroidism on progression-free survival of metastatic renal cancer patients : a prospective single-center study", Urol Oncol, 30(5), pp.704~710 (2012)
- Lee N, "Analysis of Anti-Angiogenesis-Related Adverse Events Associated with Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitors(VEGFR-TKIs)in Patients with Metastatic Renal Cell Carcinoma", Target Oncol, 18(2), pp.247~255 (2023)
- Unnikrishnan AG, "Prevalence of hypothyroidism in adults : An epidemiological study in eight cities of India", Indian J Endocrinol Metab, 17(4), pp.647~652 (2013)
- Vanderpump MP, "The epidemiology of thyroid disease", Br Med Bull, 99, pp.39~51 (2011)
- Ha J, "Sex differences in risk factors for subclinical hypothyroidism", Endocr Connect, 7(4), pp.511~522 (2018)
- Rautiola J, "Sunitinib-induced hypertension, neutropaenia and thrombocytopaenia as predictors of good prognosis in patients with metastatic renal cell carcinoma", BJU Int, 117(1), pp.110~117 (2016)
- Kucharz J, "Co-occurring adverse events enable early prediction of progression-free survival in metastatic renal cell carcinoma patients treated with sunitinib : a hypothesis-generating study", Tumori, 101(5), pp.555~559 (2015)
- Petri Bono, "Hypertension as predictor of sunitinib treatment outcome in metastatic renal cell carcinoma", Acta Oncologica, 50(4), pp.569~573 (2010)
- Vassileiadis T, "Thyroid-stimulating hormone(TSH)levels in patients with metastatic renal cell cancer treated with sunitinib", Ann Oncol, 21(Suppl 8), pp.286~ (2010)
- Buda-Nowak A, "Sunitinib-induced hypothyroidism predicts progression-free survival in metastatic renal cell carcinoma patients", Med Oncol, 34(4), pp.68~ (2017)
- Nearchou A, "Acquired Hypothyroidism as a Predictive Marker of Outcome in Patients With Metastatic Renal Cell Carcinoma Treated With Tyrosine Kinase Inhibitors : A Literature-Based Meta-Analysis", Clin Genitourin Cancer, 13(4), pp.280~286 (2015)
- Krashin E, "Thyroid Hormones and Cancer : A Comprehensive Review of Preclinical and Clinical Studies", Front Endocrinol(Lausanne), 10, pp.59~ (2019)